NCT06150703View on ClinicalTrials.gov

Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles

PHASE3RecruitingINTERVENTIONAL
Enrollment

652

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 27, 2027

Conditions
In Vitro FertilizationICSI Intracytoplasmic Spermatozoid Injection
Interventions
DRUG

Ovulation induction with hCG + Luteal phase support with vaginal progesterone

hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result

DRUG

Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin

Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test

Trial Locations (1)

Unknown

RECRUITING

Maeliss Peigné, Bondy

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER